Sanofi and Regeneron Report Phase 2 Results for Lipid Drug
Sanofi and Regeneron Pharmaceuticals, Inc. announced that data from two Phase 2 trials with
SAR236553 / REGN727 , an investigational, high-affinity, subcutaneously administered, fully-human
antibody targeting PCSK9 ( proprotein convertasesubtilisin / kexin type 9), were presented at the
American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.